Geron Corporation: Business Overview, Financials & Competitive Analysis
Geron Corporation scores 6/10 on the AskCyborg Cyborg Score (Solid). Commercial-stage biotech with validated first-in-class oncology asset showing early sales traction, but single-product concentration risk limits upside potential without pipeline diversification. In 2024, Geron's revenue reached $76.99 million, an increase of 32,386% from 2023. While revenue momentum is strong, Geron's heavy reliance on Rytelo as its primary revenue driver presents.
What is Geron Corporation's industry? Geron Corporation (geron.com) operates in Biopharmaceutical/Oncology. AskCyborg classifies Geron Corporation under Biopharmaceutical/Oncology in its company registry.
Geron is a commercial-stage biopharmaceutical company focused on developing therapeutics for oncology. The company's first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and the Eur...
Cyborg Score thesis
Commercial-stage biotech with validated first-in-class oncology asset showing early sales traction, but single-product...
Read the full analyst-debate transcript →Get the Latest Geron Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGeron Corporation Overview
Pro stress-test →Geron is a commercial-stage biopharmaceutical company focused on developing therapeutics for oncology. The company's first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. Geron achieved commercial product revenue for the first time in 2024 following FDA approval.
Strategic Profile
Pro stress-test →Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. 2026 RYTELO net product revenue is expected in the range of $220 to $240 million. The company faces significant concentration risk with a single commercial product, but benefits from first-mover advantage in telomerase inhibition for blood cancers.
Competitive Landscape
Pro stress-test →The hematologic malignancies market is highly competitive, with numerous established players and emerging biotechnology companies vying for market share. Geron faces the ongoing challenge of differentiating Rytelo from existing treatments and potential new entrants, while larger pharmaceutical companies with more extensive resources continue to invest in this therapeutic area.
Industry Context
Geron Corporation operates in Biopharmaceutical/Oncology.
Key facts
Founded: 1990 · Headquarters: Foster City, California · Revenue: $77M